292 related articles for article (PubMed ID: 24661630)
1. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes.
Delforge M; Selleslag D; Beguin Y; Triffet A; Mineur P; Theunissen K; Graux C; Trullemans F; Boulet D; Van Eygen K; Noens L; Van Steenweghen S; Lemmens J; Pierre P; D'hondt R; Ferrant A; Deeren D; Van De Velde A; Wynendaele W; André M; De Bock R; Efira A; Breems D; Deweweire A; Geldhof K; Pluymers W; Harrington A; MacDonald K; Abraham I; Ravoet C
Leuk Res; 2014 May; 38(5):557-63. PubMed ID: 24661630
[TBL] [Abstract][Full Text] [Related]
2. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
Rose C; Brechignac S; Vassilief D; Pascal L; Stamatoullas A; Guerci A; Larbaa D; Dreyfus F; Beyne-Rauzy O; Chaury MP; Roy L; Cheze S; Morel P; Fenaux P;
Leuk Res; 2010 Jul; 34(7):864-70. PubMed ID: 20129667
[TBL] [Abstract][Full Text] [Related]
3. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
[TBL] [Abstract][Full Text] [Related]
4. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications.
Remacha ÁF; Arrizabalaga B; Villegas A; Durán MS; Hermosín L; de Paz R; Garcia M; Diez Campelo M; Sanz G;
Ann Hematol; 2015 May; 94(5):779-87. PubMed ID: 25516455
[TBL] [Abstract][Full Text] [Related]
5. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
[TBL] [Abstract][Full Text] [Related]
6. Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis.
Leitch HA; Chan C; Leger CS; Foltz LM; Ramadan KM; Vickars LM
Leuk Res; 2012 Nov; 36(11):1380-6. PubMed ID: 22921191
[TBL] [Abstract][Full Text] [Related]
7. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
Leitch HA
Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
[TBL] [Abstract][Full Text] [Related]
8. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry.
Neukirchen J; Fox F; Kündgen A; Nachtkamp K; Strupp C; Haas R; Germing U; Gattermann N
Leuk Res; 2012 Aug; 36(8):1067-70. PubMed ID: 22564985
[TBL] [Abstract][Full Text] [Related]
9. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
Dreyfus F
Blood Rev; 2008 Dec; 22 Suppl 2():S29-34. PubMed ID: 19059054
[TBL] [Abstract][Full Text] [Related]
10. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Leitch HA; Parmar A; Wells RA; Chodirker L; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; Sabloff M; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Kew A; Shamy A; Elemary M; Lenis M; Mamedov A; Ivo J; Francis J; Zhang L; Buckstein R
Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
[TBL] [Abstract][Full Text] [Related]
11. Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.
Hoeks M; Yu G; Langemeijer S; Crouch S; de Swart L; Fenaux P; Symeonidis A; Čermák J; Hellström-Lindberg E; Sanz G; Stauder R; Holm MS; Mittelman M; Mądry K; Malcovati L; Tatic A; Almeida AM; Germing U; Savic A; Šimec NG; Culligan D; Itzykson R; Guerci-Bresler A; Slama B; Droste J; van Marrewijk C; van de Loosdrecht A; Blijlevens N; van Kraaij M; Bowen D; de Witte T; Smith A;
Haematologica; 2020 Mar; 105(3):640-651. PubMed ID: 31278207
[TBL] [Abstract][Full Text] [Related]
12. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
Raptis A; Duh MS; Wang ST; Dial E; Fanourgiakis I; Fortner B; Paley C; Mody-Patel N; Corral M; Scott J
Transfusion; 2010 Jan; 50(1):190-9. PubMed ID: 19719471
[TBL] [Abstract][Full Text] [Related]
13. Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
Wong SA; Leitch HA
Leuk Res; 2018 Jan; 64():24-29. PubMed ID: 29149650
[TBL] [Abstract][Full Text] [Related]
14. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy.
Wong CAC; Wong SAY; Leitch HA
Leuk Res; 2018 Apr; 67():75-81. PubMed ID: 29477023
[TBL] [Abstract][Full Text] [Related]
15. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
16. Iron overload and chelation therapy in myelodysplastic syndromes.
Temraz S; Santini V; Musallam K; Taher A
Crit Rev Oncol Hematol; 2014 Jul; 91(1):64-73. PubMed ID: 24529413
[TBL] [Abstract][Full Text] [Related]
17. Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
Merkel DG; Nagler A
Expert Rev Anticancer Ther; 2014 Jul; 14(7):817-29. PubMed ID: 24641787
[TBL] [Abstract][Full Text] [Related]
18. Iron chelation therapy in MDS: what have we learnt recently?
Schmid M
Blood Rev; 2009 Dec; 23 Suppl 1():S21-5. PubMed ID: 20116636
[TBL] [Abstract][Full Text] [Related]
19. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.
Shammo JM; Komrokji RS
Expert Rev Hematol; 2018 Jul; 11(7):577-586. PubMed ID: 29902097
[TBL] [Abstract][Full Text] [Related]
20. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
Remacha AF; Arrizabalaga B; Del Cañizo C; Sanz G; Villegas A
Ann Hematol; 2010 Feb; 89(2):147-54. PubMed ID: 19690857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]